Investors eye Vertex’s Q1 for Alyftrek and Journavx momentum amid Trikafta’s international headwinds. Vertex stock shows a bullish technical bias despite recent pullback and mixed short-term ...

Vertex Pharmaceuticals saw its share price rise by approximately 14% in the last quarter, a significant move considering the broader market's recent 1% decline. The company's legal challenges ...

LEXINGTON, Ky. (WKYT) - Skies are much calmer this morning, but we are tracking some cooler conditions. Temps for many will be in the low 50s and a few areas will see the upper 40s to start, but ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of $535, up from $480. Vertex remains well-positioned with ...

She reiterated her buy recommendation on Vertex stock, and kept her $583-per-share price target intact. According to reports, Merle's update was based on surveys with medical professionals ...

LEXINGTON, Ky. (WKYT) - Rounds of rain are set to return today, with scattered storms taking us into the weekend. Temps start much warmer in the 50s and 60s, with a few isolated showers hanging ...

ToolGen, Inc. a global leader in genome editing technology, announced that it has filed a patent infringement lawsuit in the United Kingdom against Vertex Pharmaceuticals and its commercial ...

With a market cap of $122.6 billion, Vertex Pharmaceuticals Incorporated (VRTX) operates as a global biotechnology company that develops and commercializes therapies for treating cystic fibrosis (CF).

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

According to Heather Minton, centers and community engagement coordinator, one of these programs pairs senior animals with low-income seniors and provides ownership support including access to ...